[{"id":"611d069e-ba56-4015-ba56-94bebd608133","acronym":"","url":"https://clinicaltrials.gov/study/NCT03839446","created_at":"2021-01-18T18:57:17.044Z","updated_at":"2025-02-25T13:52:47.649Z","phase":"Phase 2","brief_title":"Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy","source_id_and_acronym":"NCT03839446","lead_sponsor":"Robert Redner, MD","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2025-02-20"},{"id":"3e6558d8-f022-4465-b340-329db64b8a39","acronym":"VBP101","url":"https://clinicaltrials.gov/study/NCT04849910","created_at":"2021-04-19T11:53:06.069Z","updated_at":"2025-02-25T17:01:02.310Z","phase":"Phase 1/2","brief_title":"Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS","source_id_and_acronym":"NCT04849910 - VBP101","lead_sponsor":"Vor Biopharma","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • tremtelectogene empogeditemcel (VOR33)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-03"},{"id":"d2f2a1f1-7bb1-4919-a610-7815b806ac30","acronym":"NCI-2019-01726","url":"https://clinicaltrials.gov/study/NCT03900949","created_at":"2021-01-18T19:12:29.931Z","updated_at":"2024-07-02T16:35:01.958Z","phase":"Phase 1","brief_title":"Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03900949 - NCI-2019-01726","lead_sponsor":"Uma Borate","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" CD33 positive • CD33 expression","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Suspended","enrollment":" Enrollment 18","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-22"},{"id":"65b8b469-ba1f-453c-992d-ec880c54605c","acronym":"NCI-2018-01613","url":"https://clinicaltrials.gov/study/NCT03737955","created_at":"2021-01-18T18:18:29.778Z","updated_at":"2024-07-02T16:35:12.661Z","phase":"Phase 2","brief_title":"Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03737955 - NCI-2018-01613","lead_sponsor":"University of Washington","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/30/2018","start_date":" 11/30/2018","primary_txt":" Primary completion: 03/15/2023","primary_completion_date":" 03/15/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-27"},{"id":"1debacb5-f874-42c5-94ad-4212182706f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04980404","created_at":"2021-07-28T19:52:31.805Z","updated_at":"2024-07-02T16:35:15.753Z","phase":"Phase 1","brief_title":"Inqovi Maintenance Therapy in Myeloid Neoplasms","source_id_and_acronym":"NCT04980404","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CD33 • HLA-B","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/17/2021","start_date":" 09/17/2021","primary_txt":" Primary completion: 08/24/2023","primary_completion_date":" 08/24/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-03-08"},{"id":"417e8b04-49ba-41fb-98db-3a2a6390d025","acronym":"","url":"https://clinicaltrials.gov/study/NCT04070768","created_at":"2021-01-18T19:55:46.986Z","updated_at":"2024-07-02T16:35:26.408Z","phase":"Phase 1","brief_title":"Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113","source_id_and_acronym":"NCT04070768","lead_sponsor":"John Quigley","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" CD33 expression","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/06/2019","start_date":" 09/06/2019","primary_txt":" Primary completion: 10/12/2023","primary_completion_date":" 10/12/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-12-13"},{"id":"38aa9c92-b86b-4c71-ac1f-a0585bd922fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05987696","created_at":"2023-08-14T15:10:11.648Z","updated_at":"2024-07-02T16:35:40.228Z","phase":"Phase 1","brief_title":"Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05987696","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive • CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • CD33/CLL1 dual CAR-NK cell • Super NK cell therapy"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-11"},{"id":"f066ba35-63f6-465c-8eac-446af1756f24","acronym":"MOSAIC","url":"https://clinicaltrials.gov/study/NCT04385290","created_at":"2021-01-18T21:10:20.677Z","updated_at":"2025-02-25T15:43:59.383Z","phase":"Phase 1/2","brief_title":"Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","source_id_and_acronym":"NCT04385290 - MOSAIC","lead_sponsor":"Technische Universität Dresden","biomarkers":" FLT3 • RUNX1 • RUNX1T1","pipe":" | ","alterations":" CD33 expression","tags":["FLT3 • RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 09/04/2020","start_date":" 09/04/2020","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-08-09"},{"id":"011ff1ad-5b99-4b2d-9568-083ebcba34eb","acronym":"GALAXY33","url":"https://clinicaltrials.gov/study/NCT05662904","created_at":"2022-12-23T15:59:12.254Z","updated_at":"2024-07-02T16:35:58.632Z","phase":"Phase 1","brief_title":"Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML","source_id_and_acronym":"NCT05662904 - GALAXY33","lead_sponsor":"German Cancer Research Center","biomarkers":" CD33 • CD34","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • melphalan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-12-23"},{"id":"59ce81d4-311d-4568-926a-4dc4082edb0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03848754","created_at":"2021-01-18T18:59:49.571Z","updated_at":"2024-07-02T16:36:08.074Z","phase":"Phase 1","brief_title":"Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03848754","lead_sponsor":"Medical College of Wisconsin","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • pracinostat (SB939)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 05/24/2019","start_date":" 05/24/2019","primary_txt":" Primary completion: 05/05/2021","primary_completion_date":" 05/05/2021","study_txt":" Completion: 05/05/2021","study_completion_date":" 05/05/2021","last_update_posted":"2022-06-30"},{"id":"dd29e5ba-e01a-4bf1-babb-a8de844132f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05008575","created_at":"2021-08-17T13:52:56.750Z","updated_at":"2024-07-02T16:36:18.561Z","phase":"Phase 1","brief_title":"Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05008575","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 12/23/2021","start_date":" 12/23/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-01-12"},{"id":"7a9cc121-ee16-4092-8718-7fee4051d5ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05016063","created_at":"2021-08-23T12:52:54.408Z","updated_at":"2024-07-02T16:36:26.013Z","phase":"Phase 1","brief_title":"Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05016063","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-08-23"},{"id":"74309ad5-1915-435d-8368-58cc3daffafc","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006265","created_at":"2021-01-17T23:53:14.768Z","updated_at":"2024-07-02T16:37:30.596Z","phase":"Phase 2","brief_title":"Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT00006265","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2001","start_date":" 03/01/2001","primary_txt":" Primary completion: 12/01/2004","primary_completion_date":" 12/01/2004","study_txt":" Completion: 05/01/2005","study_completion_date":" 05/01/2005","last_update_posted":"2016-07-14"}]